No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.4490
- +0.0379+9.22%
Close Jun 14 16:00 ET
- 0.4440
- -0.0050-1.11%
Post 19:07 ET
25.65MMarket Cap-701P/E (TTM)
0.4589High0.4060Low422.24KVolume0.4160Open0.4111Pre Close183.36KTurnover0.80%Turnover RatioLossP/E (Static)57.14MShares0.748752wk High6.24P/B23.60MFloat Cap0.305452wk Low--Dividend TTM52.56MShs Float836.0000Historical High--Div YieldTTM12.87%Amplitude0.2910Historical Low0.4340Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
AIM's Membership With ACIL Changes the Game in Lab Testing
LITTLETON, Colo., June 12, 2024 /PRNewswire/ -- Analytical Instrument Management (AIM) is excited to share the news of its inclusion into the esteemed American Council of Independent Laboratories (AC
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
Live video webcast on Monday, June 17th at 1:00 PM ETOCALA, Fla., June 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, MS JD, Ch
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ETOCALA, Fla., June 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or t
Express News | ImmunoTech Announces Pricing Of 5,640,958 Share Registered Direct Offering At $0.363 Per Share; Gross Proceeds ~$2M
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
OCALA, Fla., May 31, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional in
Express News | AIM ImmunoTech Inc : Ascendiant Capital Markets Raises Target Price to $5.25 From $5
Comments
$AIM ImmunoTech(AIM.US$ AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
5
$AIM ImmunoTech(AIM.US$
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
2
$AIM ImmunoTech(AIM.US$ AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
